Date
15 November 2022
Industry Improving On LMIC Drug Access Plans But Tropical Disease R&D Lacking
Ayisha Sharma spoke to James Hazel, Research Programme Manager for the 2022 Access to Medicine Index, about some of the key findings.
Direct links
The article leads with the strides made by companies on developing access plans for their products, and more willingness to use voluntary licences to support manufacturing.
James is quoted, "A non-exclusive voluntary licence essentially enables generic manufacturers to enter the market and thus increases the availability and affordability of medicines."
The article acknowledges that despite such signs of progress, there is still much to be achieved.
Read the article on Scrip (paywall)